METHOD FOR DETERMINING THE PREDISPOSITION OF A PATIENT TO CHANGED BIOTRANSFORMATION AND TO THE DEVELOPMENT OF UNDESIRED PHARMACEUTICAL EFFECTS IN A TREATMENT OF THE PATIENT WITH ATORVASTATIN

摘要

A method for determining a predisposition of a patient to the development of muscular diseases and/or to changed biotransformation in a treatment of the patient with atorvastatin is disclosed. The presence of at least one single nucleotide polymorphism (SNP) in the UGT1A3 gene (uridine diphosphate glucuronosyltransferase gene 1A3) and/or an increased UGT1A3 gene expression is determined in a biological sample of the patient. The disclosure further relates to oligonucleotides that can be used in the method and to diagnostic kits that use the oligonucleotides.